Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Gupta, Nidhi ^a   Singh, Surjit ^a   Maturu, V Nagarjuna ^a   Sharma, Yash Paul ^a   Gill, Kiran Dip ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; OLIGONUCLEOTIDE; PARAOXON; PHENYLACETIC ACID; ARYLDIALKYLPHOSPHATASE; PHENYLACETIC ACID DERIVATIVE; PON1 PROTEIN, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; FEMALE; GENE ACTIVITY; GENE FREQUENCY; GENETIC CORRELATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; PON1 GENE; POPULATION RESEARCH; PROMOTER REGION; RISK ASSESSMENT; ENZYMOLOGY; GENETIC SCREENING; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; RISK FACTOR;

ADULT; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; FEMALE; GENETIC TESTING; GENOTYPE; HAPLOTYPES; HUMANS; INDIA; MALE; MIDDLE AGED; PARAOXON; PHENYLACETATES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79956337628     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017805     Document Type: Article

References (62)

1. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007.
2. Mackness B, Durrington PN, Mackness MI, (2002) The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 13: 357-362.
3. Cao H, Girard-Globa A, Berthezene F, Moulin P, (1999) Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 40: 133-139.
4. Shih DM, Gu L, Xia YR, Navab M, Li WF, et al. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287.
5. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, et al. (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275: 17527-17535.
6. MacKness B, Mackness MI, Durrington PN, Arrol S, Evans AE, et al. (2000) Paraoxonase activity in two healthy populations with differing rates of coronary heart disease. Eur J Clin Invest 30: 4-10.
7. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, et al. (1986) Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 32: 671-673.
8. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, et al. (1991) Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86: 193-199.
9. Richter RJ, Jarvik GP, Furlong CE, (2010) Paraoxonase 1 status as a risk factor for disease or exposure. Adv Exp Med Biol 660: 29-35.
10. Aharoni A, Gaidukov L, Khersonsky O, Mc QGS, Roodveldt C, et al. (2005) The 'evolvability' of promiscuous protein functions. Nat Genet 37: 73-76.
11. Furlong CE, Richter RJ, Chapline C, Crabb JW, (1991) Purification of rabbit and human serum paraoxonase. Biochemistry 30: 10133-10140.
12. Gan KN, Smolen A, Eckerson HW, La Du BN, (1991) Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19: 100-106.
13. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, et al. (1995) Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A 92: 7187-7191.
14. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, et al. (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14: 334-336.
15. Richter RJ, Furlong CE, (1999) Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9: 745-753.
16. Furlong CE, Holland N, Richter RJ, Bradman A, Ho A, et al. (2006) PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 16: 183-190.
17. Richter RJ, Jarvik GP, Furlong CE, (2008) Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 1: 147-152.
18. Blatter Garin MC, Abbott C, Messmer S, Mackness M, Durrington P, et al. (1994) Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 304 (Pt 2): 549-554.
19. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, et al. (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346: 869-872.
20. Schmidt H, Schmidt R, Niederkorn K, Gradert A, Schumacher M, et al. (1998) Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Stroke 29: 2043-2048.
21. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, et al. (1996) The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98: 883-885.
22. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, et al. (2002) PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 32: 9-15.
23. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, et al. (1998) The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients. Arterioscler Thromb Vasc Biol 18: 1611-1616.
24. Najafi M, Gohari LH, Firoozrai M, (2009) Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res 123: 503-510.
25. Rose HA, (1970) A glossary of the tribes and castes of Punjab and northwest frontier province. In census report language Department. Punjab 1: 55-59.
26. Singh S, Verma M, Nain CK, Leelamma CO, Goel RC, (1999) Paraoxonase (PON1) polymorphism & its relation with lipids in north west Indian Punjabis. Indian J Med Res 110: 133-137.
27. Singh S, Venketesh S, Verma JS, Verma M, Lellamma CO, et al. (2007) Paraoxonase (PON1) activity in north west Indian Punjabis with coronary artery disease & type 2 diabetes mellitus. Indian J Med Res 125: 783-787.
28. Enas EA, Yusuf S, Sharma S, (1998) Coronary artery disease in South Asians. Second meeting of the International Working Group. 16 March 1997, Anaheim, California. Indian Heart J 50: 105-113.
29. Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, et al. (1996) Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J 48: 343-353.
30. Janus ED, Postiglione A, Singh RB, Lewis B, (1996) The modernization of Asia. Implications for coronary heart disease. Council on Arteriosclerosis of the International Society and Federation of Cardiology. Circulation 94: 2671-2673.
31. McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG, (1993) Association of early-onset coronary heart disease in South Asian men with glucose intolerance and hyperinsulinemia. Circulation 87: 152-161.
32. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J, (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363: 689-695.
33. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, et al. (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21: 1451-1457.
34. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, et al. (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20: 2441-2447.
35. Sanghera DK, Saha N, Aston CE, Kamboh MI, (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17: 1067-1073.
36. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, et al. (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17: 3565-3569.
37. Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, et al. (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141: 259-264.
38. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, et al. (1996) Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57: 69-73.
39. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, et al. (2003) Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107: 2775-2779.
40. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, et al. (1996) Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 16: 1243-1249.
41. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, et al. (1998) Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139: 341-349.
42. Berkowitz GS, Wetmur JG, Birman-Deych E, Obel J, Lapinski RH, et al. (2004) In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect 112: 388-391.
43. Mackness MI, Durrington PN, Mackness B, (2000) How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 11: 383-388.
44. Blatter MC, James RW, Messmer S, Barja F, Pometta D, (1993) Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211: 871-879.
45. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN, (1997) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122: 265-268.
46. Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, et al. (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11: 77-84.
47. James RW, Leviev I, Ruiz J, Passa P, Froguel P, et al. (2000) Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49: 1390-1393.
48. Deakin S, Leviev I, Brulhart-Meynet MC, James RW, (2003) Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position- 107, implicating the Sp1 transcription factor. Biochem J 372: 643-649.
49. Leviev I, James RW, (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20: 516-521.
50. Saikawa Y, Price K, Hance KW, Chen TY, Elwood PC, (1995) Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of three clustered Sp1-binding sites with initiator region for basal promoter activity. Biochemistry 34: 9951-9961.
51. Leviev I, Righetti A, James RW, (2001) Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79: 457-463.
52. Hernandez AF, Mackness B, Rodrigo L, Lopez O, Pla A, et al. (2003) Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure. Hum Exp Toxicol 22: 565-574.
53. Suehiro T, Nakamura T, Inoue M, Shiinoki T, Ikeda Y, et al. (2000) A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150: 295-298.
54. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, et al. (2003) Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 23: 1465-1471.
55. Cambien F, (2001) Genes in population. In: Malcolm S, Goodship J, editors. Genotype to Phenotype pp. 31-53 Academic Press, Guildford, UK.
56. Hegele RA, Brunt JH, Connelly PW, (1995) A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 15: 89-95.
57. Gouedard C, Koum-Besson N, Barouki R, Morel Y, (2003) Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol Pharmacol 63: 945-956.
58. Berkowitz GS, Wolff MS, Lapinski RH, Todd AC, (2004) Prospective study of blood and tibia lead in women undergoing surgical menopause. Environ Health Perspect 112: 1673-1678.
59. Daly AK, Steen VM, Fairbrother KS, Idle JR, (1996) CYP2D6 multiallelism. Methods Enzymol 272: 199-210.
60. Eckerson HW, Wyte CM, La Du BN, (1983) The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35: 1126-1138.
61. Rompler H, Dear PH, Krause J, Meyer M, Rohland N, et al. (2006) Multiplex amplification of ancient DNA. Nat Protoc 1: 720-728.
62. Gordon D, Finch SJ, Nothnagel M, Ott J, (2002) Power and sample size calculations for case-control genetic association tests when errors are present: application to single nucleotide polymorphisms. Hum Hered 54: 22-33.